[1] Hundt H,Fleming JC,Phillips JT,et al. Assessment of hepatic inflammation after spinal cord injury using intravital microsco. Injury,2011,42（7）:691-696.
[2] Kanazawa H,Fujimoto Y,Teratani T,et al. Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. PLoS One,2011,6（4）:e19195.
[3] Panicker J,Sinha S,Taly AB,et al. Hepatic myelopathy：a rare complication following extrahepatie portal vein occlusion and lienorenal shunt. Neurol India,2006,54（3）:298-300.
[4] Meissner W,Tison F. Acquired hepatocerebral degeneration. Handb Clin Neurol,2011,100:193-197.
[5] Stracciari A,Baldin E,Cretella L,et al. Chronic acquired hepatocerebral degeneration:effects of liver transplantation on neurological manifestations. Neurol Sci,2011,32（3）:411-415.
[6] O'Brien J,Staples C,Florin T. Trouble with a shunt:alcohol and spastic paraparesis. Hepatic myelopathy. Gastroenterology, 2010,139（4）:1099,1428.
[7] Gospe SM,Caruso RD,Clegg MS,et a1. Paraparosis,hyperman-ganesaemia,and polycythaemia：a novel presentation of cirrhosis. Arch Dis Child,2000,83（5）:439-442.
[8] Upton MP,Pai RK,Vieth M,et al. Esophageal disease and pathology. Ann N Y Acad Sci,2011,1232:376-380.
[9] Li J,Tao R,Wu W,et al. Transcriptional profiling and hepatogenic potential of acute hepatic failure-derived bone marrow mesenchymal stem cells. Differentiation,2010,80（2-3）:166-174.
[10] Su AP,Cao SS,Le Tian B,et al. Effect of transjugular intrahepatic portosystemic shunt on glycometabolism incirrhosis patients. Clin Res Hepatol Gastroenterol,2012,36（1）: 53-59.
[11] Qu B,Liu C,Guo L, et al. The role of liver transplantation in the treatment of hepatic myelopathy:case report with review of the literature. Transplant Proc,2009,41（5）:1987-1989.
[12] Stutchfield BM,Rashid S,Forbes SJ,et al. Practical barriers to delivering autologous bone marrow stem cell therapy as an adjunct to liver resection. Stem Cells Dev,2010,19（2）:155-162.
[13] Zhang B,Inagaki M,Jiang B,et al. Effects of bone marrow and hepatocyte transplantation on liver injury. J Surg Res,2009,157（1）:71-80.
[14] Yurdaydin C,Idilman R. Hepatic encephalopathy. Euro Gastroenterol Hepatol Rev,2012,7（4）:268-271.
[15] 李梦东,聂青和. 应当重视亚临床肝性脑病的研究. 实用肝脏病杂志,2009,12（4）:241-243.
[16] 聂青和. 重型肝炎并发肝性脑病的诊治进展. 实用肝脏病杂志,2004,7（1）：9-12.
[17] Perryman SV,Jenkins DD,Streetz KL,et al. Hepatic injury and the kinetics of bone marrow-derived hepatocyte transgene expression. Pediatr Surg,2008,43（8）:1511-1519.
[18] Bajaj JS,Cordoba J,Mullen KD,et al. The design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism（ISHEN） consensus statement. Aliment Pharmacol Ther,2011,33（7）:739-747.
[19] Yin YH,Ma ZJ,Guan YH,et al. Clinical features of hepatic myelopathy in patients with chronic liver disease. Postgrad Med J, 2009,85（1000）:64-68.
[20] Nout YS. Gait deficits in liver disease:Hepatic encephalopathy and hepatic myelopathy. Equine Veterin Edu,2011,23（1）:11-13.
[21] Casanova-González MJ,Trapero-Marugán M,Jones EA,et al. Liver disease and erythropoietic protoporphyria:a concise review. World J Gastroenterol,2010,16（36）:4526-4531.
[22] Pinarbasi B,Kaymakoglu S,Matur Z,et al. Are acquired hepatocerebral degeneration and hepatic myelopathy reversible?J Clin Gastroenterol,2009,43（2）:176-181.
[23] Feng Z,Li C,Jiao S,et al. In vitro differentiation of rat bone marrow mesenchymal stem cells into hepatocytes. Hepatogastroenterology,2011,58（112）:2081-2086.
[24] Utku U,Asil T,Balci K,et a1. Hepatic myelopathy with spastic pamparosis. Clin Neurol Neurosurg,2005,107（6）:514-516.
[25] Spengler U. Management of end-stage liver disease in HIV/hepatitis C virus co-infection. Curr Opin HIV AIDS,2011,6（6）:527-533.
[26] Plessier A,Rautou PE,Valla DC. Management of hepatic vascular diseases. J Hepatol,2012,56 （Suppl）:S25-38.
[27] 王文清,柴叶红,杨晓莲,等. 神经肌肉本体促进技术联合功能性电刺激疗法治疗肝性脊髓病（附1例报告）.山东医药,2008,48（4）：15.
[28] 聂青和. 替诺福韦酯与拉米夫定和阿德福韦酯抗HBV疗效对比研究进展. 实用肝脏病杂志,2008,11（6）：429-432.
[29] 聂青和,周天仇. 临床肝病研究十年回顾及展望. 实用肝脏病杂志,2006,9（1）：1-4.
[30] Koo JE,Lim YS,Myung SJ,et a1. Hepatic myelopathy as a presenting neurological implication in patients with cirrhosis and spontaneous splenorenal shunt. Korean J Hepatol,2008,14（1）:89-96.
[31] Caldwell C,Werdiger N,Jakab S,et al. Use of model for end-stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature. Liver Transpl,2010,16（7）: 818-826.
[32] Khan AA,Shaik MV,Parveen N,et a1. Human fetal liver derived stem cell transplantation as supportive modality in the management of end stage decompensated liver cirrhosis.Cell Transplant,2010,47（1）:1.
[33] Shang QL,Xiao EH,Zhou QC,et al. Pathological and MR-DWI study of the acute hepatic injury model after stem cell transplantation. World J Gastroenterol,2011,17（23）:2821-2828. [34] 聂青和. 加强病毒性肝炎的基础与临床研究.胃肠病学和肝病学杂志,2007,16（1）：95-99.
[35] 李梦东,聂青和. 应重视肝功能分级及其预后评估的研究. 实用肝脏病杂志,2009,12（6）：401-406.
[36] Baccarani U,Zola E,Adani GL,et al. Reversal of hepatic myelopathy after liver transplantation:fifteen plus one. Liver Transpl,2010,16（11）:1336-1337. |
